CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 65 enrolled
Drug / intervention
Pembrolizumab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02399371
NCT02399371Phase 2Completed
CompareCT.gov

A Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Malignant Mesothelioma

University of Chicago·interventional·Posted Mar 26, 2015·Updated May 8, 2026

In Brief

A Phase 2 clinical trial evaluating Pembrolizumab, Laboratory Biomarker Analysis, and 1 other intervention for Biphasic Mesothelioma and 9 related conditions. Completed, enrolled 65 participants across 1 site.

Detailed Summary

This phase II trial studies how well pembrolizumab works in treating patients with malignant mesothelioma, a cancer of the linings around the lungs (pleura) or abdomen (peritoneum). Monoclonal antibodies, such as pembrolizumab, work by blocking a protein called programmed cell death 1 (PD-1) which may stimulate an immune response and kill tumor cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBiphasic Mesothelioma, Epithelioid Mesothelioma, Peritoneal Malignant Mesothelioma, Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Pleural Sarcomatoid Mesothelioma, Recurrent Peritoneal Malignant Mesothelioma, Recurrent Pleural Malignant Mesothelioma, Sarcomatoid Mesothelioma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 26, 2015
Enrollment StartMar 31, 2015
Primary CompletionAug 13, 2024
Study CompletionMar 20, 2026
TodayJul 2, 2026
Enrollment to primary: 9.4 yearsPosted 11.3 years ago

Interventions

Pembrolizumabbiological

Given IV

Laboratory Biomarker Analysisother

Correlative studies

Pharmacogenomic Studyother

Correlative studies